Navigation Links
It's a knock out: eIF4E-specific anti-sense oligonucleotides knock down cancer
Date:9/4/2007

A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers. As highlighted in the accompanying commentary by Celeste Simon and colleagues from the University of Pennsylvania, Philadelphia, if the therapeutic is as effective in clinical trials as it was in mice it will be useful for the treatment of a broad range of cancers.

The growth of many tumors is promoted by increased expression of the protein eIF4E, but no eIF4E-specific therapy has yet been developed. In this study, the intravenous administration of eIF4E-specific antisense oligonucleotides (ASOs) to mice bearing human tumors substantially inhibited tumor growth. Importantly, although these ASOs also decreased eIF4E expression in normal tissues, the function of the normal tissues analyzed was not compromised. The authors therefore suggest that tumor cells are more susceptible to decreased expression of eIF4E than normal cells, meaning that eIF4E-specific ASOs should not cause damage to normal tissues.

TITLE: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

AUTHOR CONTACT:

Jeremy R. Graff
Eli Lilly and Company, Indianapolis, Indiana, USA.
Phone: (317) 277-0220; Fax: (317) 277-3652; E-mail: graff_jeremy@lilly.com.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32044

ACCOMPANYING COMMENTARY:

TITLE: Taking aim at translation for tumor therapy

AUTHOR CONTACT:

M. Celeste Simon
Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 746-5532; Fax: (215) 746-5511; E-mail: celeste2@mail.med.upenn.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33107


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Alcohol a potential carcinogen: knocking on the door: pay heed!
2. Knock on the Head – No Small Thing After Al
3. Lethal Hospital Bug Tough to Knock Down, Statistics Reveal
4. The Tech Savvy Patient Knocks on the Doors of Telemedicine and Virtual Clinics
5. Knocking Out Survival Protein Could Aid Leukemia Treatment
6. Knocking Out Survival Protein Could Fight Leukemia
7. Chilean Presidents Cousin Successfully Tests Allergy Knockout Technique on Mice
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 , ... ... decreases in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Workers Compensation Research Institute (WCRI) . , According to the study, medical payments per ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance Agency, ... Hamilton County, is embarking on a charity drive with the aim of generating ... for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally owned ... clients in the northern Alabama and Georgia regions, is embarking on a charity ... Works has built a network of support and education facilities to develop and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
(Date:12/7/2016)... Atlanta, Georgia (PRWEB) , ... ... ... announced today it has acquired Presence Technology, S.L. (“Presence”) for a purchase ... certain price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch die CFDA sowie ... – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the Chinese Congress ... Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Boehringer Ingelheim announced today ... Equality Index (CEI). This is the ninth time that ... designated as a Best Place to Work for LGBT ... CEI is a national benchmarking report on corporate policies ... bisexual and transgender (LGBT) employees. "We ...
Breaking Medicine Technology: